Natixis Advisors LLC Has $2.03 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Natixis Advisors LLC increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 109.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,850 shares of the biotechnology company's stock after purchasing an additional 31,737 shares during the quarter. Natixis Advisors LLC's holdings in Exelixis were worth $2,026,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Exelixis by 18.1% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock valued at $63,000 after buying an additional 290 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Exelixis by 4.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock worth $235,000 after purchasing an additional 330 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock worth $1,937,000 after acquiring an additional 354 shares in the last quarter. Principal Securities Inc. grew its stake in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 373 shares during the last quarter. Finally, V Square Quantitative Management LLC increased its position in Exelixis by 37.3% during the fourth quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock worth $52,000 after buying an additional 425 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Remove Ads

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. The trade was a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the transaction, the director now owns 33,514 shares of the company's stock, valued at $1,248,396.50. This trade represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 in the last ninety days. Company insiders own 2.85% of the company's stock.

Exelixis Stock Down 0.0 %

Shares of EXEL traded down $0.01 during mid-day trading on Tuesday, hitting $37.71. 2,520,368 shares of the company's stock were exchanged, compared to its average volume of 2,088,242. The stock has a market cap of $10.55 billion, a price-to-earnings ratio of 21.31, a P/E/G ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The firm has a fifty day moving average of $35.66 and a two-hundred day moving average of $33.00.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

EXEL has been the subject of several analyst reports. Royal Bank of Canada boosted their price target on Exelixis from $38.00 to $40.00 and gave the company an "outperform" rating in a report on Thursday, March 13th. Oppenheimer cut shares of Exelixis from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Citigroup increased their target price on Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. Bank of America downgraded Exelixis from a "buy" rating to a "neutral" rating and raised their price objective for the stock from $35.00 to $39.00 in a report on Tuesday, December 17th. Finally, BMO Capital Markets downgraded shares of Exelixis from an "outperform" rating to a "market perform" rating and boosted their price objective for the stock from $36.00 to $40.00 in a research note on Friday, December 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.